A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma

International Journal of Cancer

Volumn 128, Issue 6, 2011, Pages 1393-1403

  Loyo, Myriam ^a   Brait, Mariana ^a   Kim, Myoung S ^a   Ostrow, Kimberly L ^a   Jie, Chunfa C ^a   Chuang, Alice Y ^a   Califano, Joseph A ^a   Liégeois, Nanette J ^b   Begum, Shahnaz ^b   Westra, William H ^b   Hoque, Mohammad O ^a   Tao, Qian ^c   Sidransky, David ^a  

^a GREATER BALTIMORE MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

biomarker; dna methylation; nasopharyngeal carcinoma

Indexed keywords

APC PROTEIN; DELETED IN COLORECTAL CARCINOMA; DELETED IN LIVER CANCER 1; ESTROGEN RECEPTOR ALPHA; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; ONCOPROTEIN; P21 ACTIVATED KINASE 3; PROTEIN AIM1; PROTEIN CALCA; PROTEIN DLEC; PROTEIN KIF1A; PROTEIN NISCH; PROTEIN PGP9 5; PROTEIN S 100; PROTEIN TIG1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SYNTHESIS; EPIGENETICS; FEMALE; GENE DELETION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; RACE DIFFERENCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79551484520     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25443     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Bhattacharyya N,. The impact of race on survival in nasopharyngeal carcinoma: a matched analysis. Am J Otolaryngol 2004; 25: 94-7.
3. Tao Q, Chan AT,. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007; 9: 1-24.
4. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L,. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970; 228: 1056-8.
5. Young LS, Rickinson AB,. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-68.
6. August M, Dodson TB, Nastri A, Chuang SK,. Nasopharyngeal carcinoma: clinical assessment and review of 176 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 205-14.
7. Sham JS, Choy D, Wei WI,. Nasopharyngeal carcinoma: orderly neck node spread. Int J Radiat Oncol Biol Phys 1990; 19: 929-33.
8. Altun M, Fandi A, Dupuis O, Cvitkovic E, Krajina Z, Eschwege F,. Undifferentiated nasopharyngeal cancer(UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995; 32: 859-77.
9. Huang DP, Ho JH, Chan WK, Lau WH, Lui M,. Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese. Int J Cancer 1989; 43: 936-9.
10. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP,. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 1188-91.
11. Fang Y, Guan X, Guo Y, Sham J, Deng M, Liang Q, Li H, Zhang H, Zhou H, Trent J,. Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer 2001; 30: 254-60. (Pubitemid 32126201)
12. Sherr CJ,. Principles of tumor suppression. Cell 2004; 116: 235-46.
13. Herman JG, Baylin SB,. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
14. Esteller M, Corn PG, Baylin SB, Herman JG,. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9.
15. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14: 97-107.
16. Stupp R, Hegi ME, Mason WP, van den, Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 434-5.
17. Kwong J, Lo KW, Chow LS, Chan FL, To KF, Huang DP,. Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int J Cancer 2005; 113: 386-92.
18. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, et al. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 2007; 26: 934-44.
19. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, Jin J, Liu D, Rhim JS, Rha SY, Loyo M, Chan AT, et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS ONE 2008; 3: e2990.
20. Kwong J, Chow LS, Wong AY, Hung WK, Chung GT, To KF, Chan FL, Daigo Y, Nakamura Y, Huang DP, Lo KW,. Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer 2007; 46: 171-80.
21. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP,. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 2004; 10: 2401-6.
22. Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP,. Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient. Clin Cancer Res 2003; 9: 1033-8. (Pubitemid 36323708)
23. Slaughter DP, Southwick HW, Smejkal W,. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
24. Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE,. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 1997; 100: 2133-7.
25. Li YH, Shao JY, Zhao MQ, Gao HY, Li LR, Guan ZZ, Zeng YX,. Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy. Ai Zheng 2003; 22: 645-8.
26. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, Caballero OL, Westra WH, Sidransky D, Hoque MO,. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 2786-94.
27. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, Osada M, Mori M, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005; 65: 4963-8.
28. Gallicchio L, Matanoski G, Tao XG, Chen L, Lam TK, Boyd K, Robinson KA, Balick L, Mickelson S, Caulfield LE, Herman JG, Guallar E, et al. Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: a systematic review. Int J Cancer 2006; 119: 1125-35.
29. Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, Zhao M, Jeronimo C, Henrique R, Nayak CS, Park HL, Brait MR, et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res 2006; 66: 9401-7.
30. Mosmann T,. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
31. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, Jeronimo C, Henrique R, Lendvai A, Schuuring E, Begum S, et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 2008; 68: 2661-70.
32. Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, Argani P, Westra W, Van Criekinge W, Sidransky D,. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res 2009; 15: 1184-91.
33. Ray ME, Wistow G, Su YA, Meltzer PS, Trent JM,. AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc Natl Acad Sci USA 1997; 94: 3229-34.
34. Yonekawa Y, Harada A, Okada Y, Funakoshi T, Kanai Y, Takei Y, Terada S, Noda T, Hirokawa N,. Defect in synaptic vesicle precursor transport and neuronal cell death in KIF1A motor protein-deficient mice. J Cell Biol 1998; 141: 431-41.
35. Horii J, Hiraoka S, Kato J, Saito S, Harada K, Fujita H, Kaji E, Yamamoto K,. Methylation of estrogen receptor 1 in colorectal adenomas is not age-dependent, but is correlated with K-ras mutation. Cancer Sci 2009; 100: 1005-11.
36. Issa JP, Baylin SB, Belinsky SA,. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 1996; 56: 3655-8.
37. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, Sidransky D,. The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 2008; 123: 753-9.
38. Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, Fabbri A, Andriani F, Brambilla C, Tavecchio L, Calarco G, Calabro E, et al. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. Am J Respir Crit Care Med 2009; 179: 396-401.
39. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC,. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998; 58: 2196-9.
40. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS,. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. New Engl J Med 2004; 350: 2461-70.
41. Yu KH, Lo YM, Tse GM, Chan KC, Chan AB, Chow KC, Ma TK, Vlantis AC, Leung SF, van, Hasselt CA, Johnson PJ, Chan AT,. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas. Clin Cancer Res 2004; 10: 1726-32.
42. Waki T, Tamura G, Sato M, Motoyama T,. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 2003; 22: 4128-33.
43. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE,. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 1998; 395: 801-4.
44. Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y,. Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res 1994; 54: 3007-10.
45. Yuan BZ, Yang Y, Keck-Waggoner CL, Zimonjic DB, Thorgeirsson SS, Popescu NC,. Assignment and cloning of mouse Arhgap7 to chromosome 8A4-B2, a conserved syntenic region of human chromosome 8p22->p21. Cytogenet Cell Genet 1999; 87: 189-90.
46. Kawai K, Iwamae Y, Yamaga M, Kiyota M, Ishii H, Hirata H, Homma Y, Yagisawa H,. Focal adhesion-localization of START-GAP1/DLC1 is essential for cell motility and morphology. Genes Cells 2009; 14: 227-41.
47. Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC, Urquidi V,. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 2005; 65: 6042-53.